LNAI
Lunai BioworksFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Clinical proof-of-concept or a favorable partnership could unlock sizeable upside given the current low market capitalization and limited analyst coverage; expectation is material re-rating toward biotech peers on positive data.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Trial failure, extended cash runway concerns, or dilutive financing could push the stock materially lower; illiquidity can exacerbate downside on negative headlines.
Momentum
8
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.06 · Bull $1.60 · Bear $0.60
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum8 · Δ7d -
Value41 · Δ7d -0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
8
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 8.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$11.97M
Beta
0.45
Shares Out
4.53M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.29
Rev YoY
-100.0%
EPS YoY
-994.6%
Gross Margin
-360.7%
Op Margin
-
Net Debt
$9.96M
Current Ratio
0.19
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology